---
title: "Multidose Psilocybin for Obsessive-Compulsive Disorder: Open-Label Randomized Trial Results"
id: "medrxiv-10-an-open-label-multidose-psilocybin-intervention-for-obsessive-compulsive"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-10-an-open-label-multidose-psilocybin-intervention-for-obsessive-compulsive"
content_type: "clinical_feed_article"
specialty: "General"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.10.01.26364511v1?rss=1"
published_at: "2026-10-05T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Multidose Psilocybin for Obsessive-Compulsive Disorder: Open-Label Randomized Trial Results
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-10-an-open-label-multidose-psilocybin-intervention-for-obsessive-compulsive
- **Specialty:** [General](https://medichelpline.com/clinical-feed/general.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.10.01.26364511v1?rss=1)
- **Published At:** 2026-10-05T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This open-label, waitlist-controlled randomized trial evaluated feasibility, safety, and preliminary efficacy of **psilocybin** administered in two doses for adults with **Obsessive-Compulsive Disorder (OCD)** who had previously not responded to pharmacotherapy or evidence-based psychotherapy. - The study was conducted at Johns Hopkins University School of Medicine and randomized 37 participants by age, sex, and OCD severity; 30 completed the 1-month follow-up. - Intervention consisted of two supervised psilocybin sessions given over two weeks: an initial 20 mg dose followed by 30 mg if the first dose was well-tolerated. - The immediate-treatment arm (N=16) received dosing within a month after enrollment; the waitlist-control arm (N=14) received identical support and dosing after an 8-week waiting period. - Primary clinician-rated outcome was Yale-Brown Obsessive-Compulsive Scale (**Y-BOCS**), assessed one week after each dose and one month after the second session. - Secondary assessments included acute subjective effect measures (Mystical Experience Questionnaire **MEQ**, Challenging Experience Questionnaire **CEQ**, 11-Dimensional Altered States of Consciousness **11D-ASC**), State-Trait Anxiety Inventory (**STAI**), Beck Depression Inventory-II (**BDI-II**), and Quality of Life Enjoyment and Satisfaction Questionnaire (**Q-LES-Q**). - The immediate-treatment group showed a greater reduction in Y-BOCS compared with waitlist (F(2,56)=16.17, p<0.001); after crossover, improvements persisted one month after the second dose for both groups (F(3,84)=29.91, p<0.001). - Reductions in Y-BOCS after sessions correlated with total MEQ scores and specific factors on CEQ and 11D-ASC, suggesting links between acute subjective experiences and OCD symptom change. - Two successive psilocybin doses over two weeks were reported as well-tolerated in this sample; full safety details and adverse event specifics were not exhaustively reported in the abstract. - The trial is registered (ClinicalTrials.gov NCT05546658) and received IRB approval from Johns Hopkins School of Medicine (IRB00284207). Data are available on request. Philanthropic support was declared; several authors reported relevant competing interests.
## Clinical Analysis & Structured Key Points
An Open-Label Multidose Psilocybin Intervention for Obsessive-Compulsive Disorder. | medRxiv Skip to main content An Open-Label Multidose Psilocybin Intervention for Obsessive-Compulsive Disorder. View ORCID Profile Praachi Tiwari , View ORCID Profile Sandeep M Nayak , View ORCID Profile Nathan D Sepeda , View ORCID Profile Rebecca Ehrenkranz , View ORCID Profile Michael A Levine , View ORCID Profile Julia S Rohde , View ORCID Profile Eliza Miller , View ORCID Profile Carina M Beritela , View ORCID Profile Jeremy V Scott , Gerald Nestadt , View ORCID Profile Frederick S Barrett , View ORCID Profile David B Yaden doi: https://doi.org/10.64898/2026.10.01.26364511 Praachi Tiwari 1 Johns Hopkins Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Praachi Tiwari Sandeep M Nayak 1 Johns Hopkins Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Sandeep M Nayak Nathan D Sepeda 1 Johns Hopkins Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Nathan D Sepeda Rebecca Ehrenkranz 1 Johns Hopkins Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Rebecca Ehrenkranz Michael A Levine 1 Johns Hopkins Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Michael A Levine Julia S Rohde 1 Johns Hopkins Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Julia S Rohde Eliza Miller 1 Johns Hopkins Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Eliza Miller Carina M Beritela 2 Johns Hopkins Hospital Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Carina M Beritela Jeremy V Scott 1 Johns Hopkins Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Jeremy V Scott Gerald Nestadt 1 Johns Hopkins Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Frederick S Barrett 1 Johns Hopkins Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Frederick S Barrett David B Yaden 1 Johns Hopkins Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for David B Yaden For correspondence: dyaden1{at}jh.edu Abstract Info/History Metrics Data/Code Preview PDF Abstract Importance: Obsessive-Compulsive Disorder (OCD) has a 2% global prevalence, but only about 50% of patients respond to conventional treatment, underscoring the need for additional effective interventions. Objective: To assess the feasibility, safety, and preliminary evidence for efficacy of repeated psilocybin administration in OCD patients who had previously attempted psychotherapy or pharmacotherapy. Design: Waitlist-controlled open label randomized clinical trial. Setting: Data were collected at the Johns Hopkins University School of Medicine. Participants: Data were analyzed from 30 participants (total randomized N=37, by age, sex and OCD severity) with a failed previous attempt at either pharmacotherapy or evidence-based psychotherapies such as exposure response prevention (ERP). Intervention: Participants received two psilocybin doses over two weeks (20 mg followed by 30 mg, if well-tolerated) under supportive conditions. The immediate-treatment arm received the drug within a month following enrollment, and the waitlist-control arm received identical support and dosing after an 8-week waiting period. Main Outcomes: Clinician-administered Y-BOCS scores was collected one week post each drug administration and one month post session 2. Self-assessed reports were collected for acute subjective effects (Mystical Experience Questionnaire (MEQ), Challenging Experience Questionnaire (CEQ), and 11-Dimensional Altered States of Consciousness (11D-ASC)), State-Trait Anxiety Inventory (STAI), Beck Depression Inventory-II (BDI-II), and Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q). Results: A total of 37 participants were enrolled in the study (age[SD] years:38.4[11.6] years; 21 [56.75%] female), with 30 [81.08%] completing the 1-month follow-up. We show that two successive doses of psilocybin over two weeks were well-tolerated, leading to improvements in OCD symptoms. Compared with the waitlist group (N=14), the immediate-treatment group (N=16) showed a greater reduction in the Y-BOCS scores (F(2,56)=16.17, p<0.001). After crossover, this improvement persisted one month after the second psilocybin dose for both groups (F(3,84)=29.91, p<0.001). Reductions in Y-BOCS score post sessions were correlated with several acute subjective effects measures, including total scores on MEQ, and individual factors on CEQ and 11D-ASC. Conclusions and Relevance: Repeated psilocybin administration is tolerable and potentially efficacious in reducing OCD symptoms. These results support further investigation of multidose psilocybin protocols as a viable therapeutic approach. Trial Registration: ClinicalTrials.gov Identifier NCT05546658 Competing Interest Statement SMN has consulted for Resilient Pharmaceuticals and MMS Holdings. NS serves as a paid Data and Safety Monitoring Board (DSMB) member for PT2PC, a clinical trial of psilocybin therapy for palliative care. FSB has been paid as a scientific advisor and hold stock in MindState Design Labs, LLC, and I am also a scientific advisor for Mind Pharmaceuticals. DBY has received research support from the NIH, the Heffter Research Institute, the Gracias Family Foundation, and philanthropic donors to the Johns Hopkins Center for Psychedelic and Consciousness Research. He co-directs the Hub at Oxford for Psychedelic Ethics (HOPE), which has received a small anonymous donation to support travel for underrepresented workshop participants; DBY does not personally receive financial support for this role. DBY has received consulting a fee from Soneira and educational speaking fees from the Integrative Psychiatry Institute. Clinical Trial NCT05546658 Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: IRB of Johns Hopkins School of Medicine gave ethical approval for this work under IRB00284207. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability All data produced in the present study are available upon reasonable request to the authors. Funder Information Declared Funded with philanthropic support from Charlie Scheeler and Mary Ellen Pease. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Back to top Previous Next Posted October 05, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following An Open-Label Multidose Psilocybin Intervention for Obsessive-Compulsive Disorder. Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share An Open-Label Multidose Psilocybin Intervention for Obsessive-Compulsive Disorder. Praachi Tiwari , Sandeep M Nayak , Nathan D Sepeda , Rebecca Ehrenkranz , Michael A Levine , Julia S Rohde , Eliza Miller , Carina M Beritela , Jeremy V Scott , Gerald Nestadt , Frederick S Barrett , David B Yaden medRxiv 2026.10.01.26364511; doi: https://doi.org/10.64898/2026.10.01.26364511 Share This Article: Copy Citation Tools An Open-Label Multidose Psilocybin Intervention for Obsessive-Compulsive Disorder. Praachi Tiwari , Sandeep M Nayak , Nathan D Sepeda , Rebecca Ehrenkranz , Michael A Levine , Julia S Rohde , Eliza Miller , Carina M Beritela , Jeremy V Scott , Gerald Nestadt , Frederick S Barrett , David B Yaden medRxiv 2026.10.01.26364511; doi: https://doi.org/10.64898/2026.10.01.26364511 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (625) Allergy and Immunology (913) Anesthesia (340) Cardiovascular Medicine (4883) Dentistry and Oral Medicine (484) Dermatology (421) Emergency Medicine (658) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1641) Epidemiology (16056) Forensic Medicine (34) Gastroenterology (1218) Genetic and Genomic Medicine (7123) Geriatric Medicine (736) Health Economics (1072) Health Informatics (5117) Health Policy (1447) Health Systems and Quality Improvement (1792) Hematology (589) HIV/AIDS (1355) Infectious Diseases (except HIV/AIDS) (16352) Intensive Care and Critical Care Medicine (1183) Medical Education (677) Medical Ethics (156) Nephrology (729) Neurology (7377) Nursing (370) Nutrition (1101) Obstetrics and Gynecology (1261) Occupational and Environmental Health (1010) Oncology (3655) Ophthalmology (1066) Orthopedics (399) Otolaryngology (459) Pain Medicine (483) Palliative Medicine (142) Pathology (711) Pediatrics (1821) Pharmacology and Therapeutics (741) Primary Care Research (775) Psychiatry and Clinical Psychology (5979) Public and Global Health (9829) Radiology and Imaging (2461) Rehabilitation Medicine and Physical Therapy (1478) Respiratory Medicine (1256) Rheumatology (648) Sexual and Reproductive Health (785) Sports Medicine (588) Surgery (786) Toxicology (107) Transplantation (310) Urology (297)
## Related Clinical Research

- [Global study finds women report more pain than men across 11 body sites](https://medichelpline.com/clinical-feed/medical-news-today-0-women-consistently-experience-more-pain-than-men-across-11-body-parts.md)
- [Prenatal Alcohol and Smoking Patterns Linked to Maternal Depression and Anxiety Across the Perinat](https://medichelpline.com/clinical-feed/medrxiv-8-patterns-of-substance-use-during-pregnancy-are-differentially-associated-with.md)
- [Men with Multiple Long-Term Conditions and Disability in the Game of Stones Weight Management Trial](https://medichelpline.com/clinical-feed/bmj-open-2-mens-experiences-of-multiple-long-term-conditions-and-or-disability-in-the-uk.md)
- [Multimorbidity and mental health in older Chinese adults: how family and social support modify risk](https://medichelpline.com/clinical-feed/plos-one-23-chronic-disease-multimorbidity-and-mental-health-among-older-adults-in-china.md)
- [End-of-life symptom prevalence and drivers among hospital decedents in South Korea](https://medichelpline.com/clinical-feed/plos-one-3-prevalence-and-influencing-factors-of-end-of-life-symptoms-among-hospital.md)

## Navigation
- [← Back to General Feed](https://medichelpline.com/clinical-feed/general.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.